Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced ...

Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative ...

The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate complement activation independent of the classical ... of the alternative pathway of complement.

Researchers at the Tohoku University Graduate School of Medicine have uncovered a key primary step in the hepatic ERK pathway ...

In the recent article, “Antisense Oligonucleotide Therapy for Calmodulinopathy,” we provided the first proof-of-concept in ...

At close: 4:00:01 p.m. EDT ...